Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy.
Specifically, Liora has created the LiGHT System, which is believed to provide many advantages over other proton therapy methods and systems that are currently available. While it is smaller in size, the system can be deployed quickly and is much more cost-effective to build and use.
The system also eliminates mechanical energy degraders, reduces proton loss and enables more efficiency as it adjusts energy electronically. It also allows for much more precise dosing and lets you change energy levels much faster than many other methods.
The LiGHT system synergizes incredibly well with LIXTE’s lead clinical candidate and main product, LB-100, a proprietary small-molecule inhibitor of protein phosphatase 2A (“PP2A”) that boosts the activity and effectiveness of chemotherapy and immunotherapy. It has demonstrated a favorable safety profile in Phase 1 clinical trials and is supported by more than two dozen published preclinical and translational studies. The compound is currently being evaluated in multiple clinical programs targeting solid tumors with limited treatment options.
Together, the companies, and their flagship products and systems, are building a new cancer care ecosystem. Specifically, Liora’s radiotherapy technology complements LIXTE’s LB-100 approach.
The LiGHT System works to effectively destroy cancer cells by precisely delivering the right amount of radiation in the right spots. This synergizes well with LB-100, as the compound not only makes cancer cells more vulnerable to the radiation, but also helps to prevent these cancer cells from being able to repair themselves after being damaged.
Simply put, the LB-100 may weaken the cancer cells, thus boosting how well the radiation from the LiGHT System is able to damage them, while also preventing the cells from being able to recover after being damaged by the radiation.
As a result, the pair has the potential to become a multi-modal cancer care platform that helps patients enjoy more effective cancer treatments. The acquisition allows LIXTE to test the drug-device combo in trials and see just how much more effective and efficient the ecosystem may be than other currently available methods.
About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that’s developing cancer therapies built around a novel biological target. Instead of introducing standalone treatments, the company is focused on enhancing the effectiveness of established cancer therapies and addressing challenges that limit outcomes in oncology.
For more information, visit the company website at https://lixte.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com
TinyGems is powered by IBN
As Chinese artificial intelligence (AI) continues to pressure leading Western models, lawmakers and industry leaders…
Research published in the journal Nature Medicine has revealed that experimental immunotherapy may provide some relief to patients with…
A new study suggests that theratio of two common dietary fats may profoundly influence how…
The current administration’s approach to clean energy policy has led to the cancellation of $83 billion worth of…
Meta has removed its newly launched Muse Image tool after facing widespread backlash over privacy concerns and…
A research team investigating children's brain tumors has found promising results combining a hormone treatment with…